Penumbra Inc. (PEN)
PEN trades on NYSE in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1321732/000132173226000007/0001321732-26-000007-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PEN on NYSE |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001321732 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.4B |
| Net income | $177.7M |
| Operating income | $189.2M |
| Net margin | 12.7% |
| Operating margin | 13.5% |
| Revenue growth | +17.5% |
| Cash | $186.9M |
| Total assets | $1.8B |
| P/E (computed) | 71.1× |
| P/S (computed) | 9.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $254.3M cash; operating cash flow $65.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 39,414,385 (2026-10-14); 39,162,177 a year earlier; 38,596,366 three years earlier. | Cover page 2026-10-14 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $11.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $410.1M | $42.3M | $41.5M | $254.3M | No debt tags | $1.6B | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $390.0M | $34.8M | $46.1M | $205.3M | No debt tags | $1.5B | 10-Q 2026-07-30 |
| Q1 2026 2026-03-31 | $374.8M | $32.6M | $87.0M | $241.3M | No debt tags | $1.5B | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $385.4M | $47.3M | $86.5M | $186.9M | No debt tags | $1.4B | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $354.7M | $45.9M | $58.3M | $321.0M | No debt tags | $1.3B | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $339.5M | $45.3M | $44.9M | $421.8M | No debt tags | $1.3B | 10-Q 2026-07-30 |
| Q1 2025 2025-03-31 | $324.1M | $39.2M | $49.0M | $376.1M | No debt tags | $1.2B | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $315.5M | $33.7M | $51.1M | $324.4M | No debt tags | $1.2B | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2023-02-23 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 956 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | +0.3% |
| 3 months | -1.8% |
| Year to date | +3.2% |
| 1 year | +15.1% |
| From 52-week high | -10.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BAX | Baxter International Inc. | $25.54 | -1.05% | $13.2B |
| GKOS | Glaukos Corporation | $244.88 | -0.34% | $14.5B |
| SOLV | Solventum Corporation | $88.65 | -0.48% | $15.0B |
| PODD | Insulet Corporation | $145.29 | -4.72% | $10.1B |
| GMED | Globus Medical Inc. | $70.50 | -2.27% | $9.3B |
| TFX | Teleflex Incorporated | $157.10 | +1.51% | $6.2B |
| HAE | Haemonetics Corporation | $121.34 | -1.30% | $5.5B |
| WST | West Pharmaceutical Services Inc. | $417.80 | +0.33% | $29.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier